Comparative Pharmacology
Head-to-head clinical analysis: ULTRAVIST 300 IN PLASTIC CONTAINER versus VARIBAR PUDDING.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ULTRAVIST 300 IN PLASTIC CONTAINER versus VARIBAR PUDDING.
ULTRAVIST 300 IN PLASTIC CONTAINER vs VARIBAR PUDDING
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopromide is a nonionic, low-osmolality iodinated contrast medium that attenuates X-rays due to its iodine content (300 mg iodine/mL). It provides radiographic contrast in vascular and parenchymal imaging by increasing the density of blood vessels and tissues, thereby enhancing the visibility of structures and lesions.
Barium sulfate acts as a radiopaque contrast agent. It has high atomic number (z=56) and density, which attenuates X-rays and provides positive contrast in the gastrointestinal tract. It is not absorbed systemically and coats the mucosal surface, allowing visualization of luminal anatomy and pathology.
Intravenous administration of 1-2 mL/kg (300 mg iodine/mL) for contrast-enhanced CT; typical adult dose 100-150 mL (30-45 g iodine) given as bolus or rapid infusion.
125 mL orally once for upper GI studies; 250-500 mL orally once for small bowel follow-through. Not for IV use.
None Documented
None Documented
Terminal half-life: 2 hours in patients with normal renal function; prolonged up to 30 hours in severe renal impairment (CrCl <30 mL/min).
Not applicable; barium sulfate is not absorbed systemically; gastrointestinal transit time is approximately 1–2 hours for gastric emptying and 6–24 hours for colonic passage.
Renal: 90% unchanged via glomerular filtration within 24 hours; biliary: <1%; fecal: <2%.
Varibar (barium sulfate) is not absorbed from the GI tract; it is excreted unchanged in feces. 100% fecal elimination as unabsorbed barium sulfate.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent